- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | Cantor Fitzgerald initiates Compass Therapeutics stock with Overweight rating | 1 | Investing.com | ||
| COMPASS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.12. | Compass Therapeutics stock initiated at Market Outperform by Citizens | 1 | Investing.com | ||
| 25.11. | Compass Therapeutics to Participate in Upcoming December Investor Events | 2 | GlobeNewswire (USA) | ||
| 18.11. | Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development | 3 | Insider Monkey | ||
| 05.11. | Compass Therapeutics GAAP EPS of -$0.08 beats by $0.06 | 1 | Seeking Alpha | ||
| 05.11. | Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 96 | GlobeNewswire (Europe) | Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC)... ► Artikel lesen | |
| 05.11. | Compass Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Compass Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 26.08. | Compass Therapeutics to Participate in Upcoming September Investor Events | 2 | GlobeNewswire (USA) | ||
| 13.08. | Compass Therapeutics dips 5%, prices $120M stock | 1 | Seeking Alpha | ||
| 13.08. | Compass Therapeutics prices $120 million public offering of common stock | 2 | Investing.com | ||
| 13.08. | Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 12.08. | Compass Therapeutics Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 12.08. | Guggenheim raises Compass Therapeutics stock price target on promising clinical data | 3 | Investing.com | ||
| 11.08. | Compass Therapeutics: Raymond James bestätigt "Outperform"-Rating trotz verzögerter Studienergebnisse | 3 | Investing.com Deutsch | ||
| 11.08. | Compass Therapeutics stock holds Outperform rating at Raymond James | 3 | Investing.com | ||
| 11.08. | Compass Therapeutics rises after pipeline updates | 3 | Seeking Alpha | ||
| 11.08. | Compass Therapeutics GAAP EPS of -$0.14 misses by $0.02 | 1 | Seeking Alpha | ||
| 11.08. | Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update | 343 | GlobeNewswire (Europe) | In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | +0,19 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CUREVAC | 4,262 | -0,37 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| AMGEN | 276,75 | -0,04 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,608 | +0,07 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 148,65 | -0,57 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| MAINZ BIOMED | 1,030 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,210 | +1,36 % | This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street | ||
| INTELLIA THERAPEUTICS | 7,692 | -1,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 59,00 | +0,85 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,384 | -1,24 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,470 | 0,00 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,275 | -0,33 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| EXELIXIS | 35,420 | +0,60 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,36 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,893 | +2,29 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen |
COMPASS THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,84 % bei einem Aktienkurs von 5,065 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COMPASS THERAPEUTICS INC finden Sie auf Wallstreet Online.